Loading...
•
Sep 30, 2020
Arbutus Q3 2020 Earnings Report
Reported third quarter financial results and provided a corporate update.
Key Takeaways
Arbutus Biopharma reported its third quarter 2020 financial results. The company had cash, cash equivalents and investments totaling $118.3 million as of September 30, 2020. Net loss attributable to common shares for the three months ended September 30, 2020 was $21.8 million ($0.27 basic and diluted loss per common share).
Ongoing Phase 1a/1b clinical trial for Arbutus’ AB-729 to be presented at AASLD Conference.
Clinical collaboration with Assembly Biosciences, Inc. established to evaluate Arbutus’ AB-729 in combination with vebicorvir.
AB-836, Arbutus’ oral capsid inhibitor, remains on track for completion of CTA/IND-enabling studies by the end of 2020
Arbutus had cash, cash equivalents and investments totaling $118.3 million as of September 30, 2020
Forward Guidance
Arbutus believes its ending third quarter cash, cash equivalents and investments of $118.3 million are sufficient to fund the Company’s operations into mid-2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...